Vera Therapeutics Management
Management criteria checks 2/4
Vera Therapeutics' CEO is Marshall Fordyce, appointed in May 2016, has a tenure of 9.33 years. total yearly compensation is $5.65M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $7.12M. The average tenure of the management team and the board of directors is 1.7 years and 4.9 years respectively.
Key information
Marshall Fordyce
Chief executive officer
US$5.6m
Total compensation
| CEO salary percentage | 10.91% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.7yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Jun 27
Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)
Jun 04Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Mar 14Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?
Mar 07Vera Therapeutics: Strong Data In IgAN, But We May Be Too Late
Dec 22Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?
Oct 07Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Oct 04Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
Jul 22Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?
Jul 05Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$218m |
| Mar 31 2025 | n/a | n/a | -US$175m |
| Dec 31 2024 | US$6m | US$616k | -US$152m |
| Sep 30 2024 | n/a | n/a | -US$134m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$3m | US$586k | -US$96m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$107m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$4m | US$551k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$73m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$45m |
| Dec 31 2021 | US$1m | US$479k | -US$33m |
| Sep 30 2021 | n/a | n/a | -US$59m |
| Jun 30 2021 | n/a | n/a | -US$55m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$360k | -US$53m |
Compensation vs Market: Marshall's total compensation ($USD5.65M) is about average for companies of similar size in the US market ($USD5.55M).
Compensation vs Earnings: Marshall's compensation has increased whilst the company is unprofitable.
CEO
Marshall Fordyce (51 yo)
Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.3yrs | US$5.65m | 0.45% $ 7.1m | |
| Chief Legal Officer | less than a year | US$5.83m | no data | |
| Chief Medical Officer | 1.7yrs | US$4.46m | 0.0019% $ 29.7k | |
| Chief Financial Officer | 4.2yrs | US$1.76m | 0.071% $ 1.1m | |
| Chief Opearating Officer | 1.2yrs | no data | no data | |
| Senior VP of Finance & Chief Accounting Officer | 4.3yrs | no data | 0.046% $ 726.0k | |
| Executive Vice President of Research | 1.7yrs | US$397.02k | no data | |
| Senior VP of Legal | less than a year | no data | no data | |
| Vice President of Corporate Communications | less than a year | no data | no data | |
| Vice President of Marketing | less than a year | no data | no data | |
| Senior Vice President of Human Resources | 3.7yrs | no data | no data | |
| Executive Vice President of Development Operations | 5.5yrs | no data | no data |
Experienced Management: VERA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.3yrs | US$5.65m | 0.45% $ 7.1m | |
| Independent Director | 4.9yrs | US$436.59k | 0% $ 0 | |
| Independent Chairman of the Board | 3.3yrs | US$471.59k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$438.59k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$436.59k | 0.21% $ 3.4m | |
| Independent Director | 5.4yrs | US$446.59k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$437.59k | 0.027% $ 432.8k | |
| Independent Director | 1.3yrs | US$775.40k | 0.0047% $ 73.9k | |
| Independent Director | 3.8yrs | US$432.59k | 0% $ 0 |
Experienced Board: VERA's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/09 20:13 |
| End of Day Share Price | 2025/09/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vera Therapeutics, Inc. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Liisa Bayko | Evercore ISI |
| Paul Choi | Goldman Sachs |